“…A few nonrandomized studies found that some QoL benefits were associated with LT4 + LT3 combination therapy ( Table 3 ). In an open-label longitudinal cohort study of a switch to LT4 + LT3, Michaelsson et al (2018) reported that the ThyPRO-39 score fell (indicating a reduction in symptoms of hypothyroidism and better QoL) from 54 [ 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 ] at baseline to 15 [ 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ,…”